Insurance coverage for GLP-1 medications is genuinely inconsistent, and that inconsistency is one of the biggest drivers of the compounding and telehealth markets this site covers elsewhere. Here's the general shape of how coverage decisions get made.
Diagnosis Matters More Than Drug
The same medication can be covered very differently depending on the diagnosis code attached to the prescription. Semaglutide prescribed for type 2 diabetes (as Ozempic) is far more consistently covered by insurance than the identical compound prescribed for weight management (as Wegovy), even though it's the same active ingredient. Insurers have historically treated obesity treatment as a separate, often excluded, benefit category from diabetes treatment, a distinction that shapes coverage far more than the chemistry of the drug itself.
Employer Plan Decisions
For people with employer-sponsored insurance, coverage of weight-management GLP-1s is frequently a specific benefit design choice made by the employer, not a blanket insurer policy. Because these medications are expensive at scale, some employers have opted out of covering them for weight management specifically, while others have added coverage as a recruitment or retention benefit, meaning two employees on the same insurance carrier's network but different employer plans can have completely different coverage.
Medicare and Medicaid
Medicare Part D has historically been restricted from covering drugs specifically for weight loss, though coverage rules have been the subject of ongoing policy debate and periodic legislative proposals to change that. Medicaid coverage varies by state, with some states covering GLP-1s for weight management and others not, adding another layer of geographic inconsistency to an already uneven picture.
Manufacturer Savings Programs
Partly in response to this coverage gap, manufacturers have offered savings cards and cash-pay programs that can significantly reduce out-of-pocket costs for eligible patients, though eligibility, pricing, and program structure have shifted more than once and are worth checking directly rather than assuming based on older information.
Why This Drives the Compounding Market
The combination of high list prices and inconsistent coverage is a major reason patients have sought out compounded alternatives, which sidestep insurance entirely with lower cash prices. Understanding this coverage landscape helps explain why the compounding and telehealth markets grew as fast as they did, and why policy changes to insurance coverage would likely reshape demand for those alternatives as well.
Prior Authorization Hurdles
Even when a plan technically covers a GLP-1 medication, prior authorization requirements, documentation of a specific BMI threshold, prior attempts at other weight-management approaches, or specific diagnosis codes, can add significant delay and paperwork before approval. These requirements are a meaningful, if less visible, part of why so many patients turn to cash-pay or compounded alternatives even when their plan nominally covers the drug.